LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

LENZ Therapeutics, Inc. (LENZ) is a Biotechnology company based in US with a market capitalization of $161.8M. Free cash flow was negative at -$70M. This page tracks LENZ's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 6 employees · IPO Mar 22, 2024

Valuation

Valuation & price

$7.34as of May 17, 2026· -85.0% vs 52w high

P/E ratio

Latest-FY diluted EPS

0.57

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$48.60$26.77$4.93Jul 25Jan 26Jul 26
$4.8852-week range$49.05
Loading valuation history…

Fundamentals

Key fundamentals

$161.8M

Market cap

Revenue growth (YoY)

96.3%

Gross margin

-$70M

Free cash flow (USD)

-$292M

Net debt

Net cash position

35.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20192025

$0$19.1M

Free cash flow by year

20192025

-$19K-$70M

Gross margin by year

20222025

100.0%96.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJul 2, 2026Filing

    Board Member Resignation

  • 8-K eventJun 12, 2026Filing

    Annual Meeting Results

  • 8-K eventMay 11, 2026Filing

    Earnings Release

  • Quarterly reportMay 11, 2026Filing

    10-Q Filed

Questions

Frequently asked questions

What is LENZ Therapeutics, Inc.'s market cap?

LENZ Therapeutics, Inc. (LENZ) has a market capitalization of $161.8M.

What is LENZ's P/E ratio?

A meaningful P/E ratio is not available for LENZ — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LENZ's price-to-book (P/B) ratio?

LENZ trades at 0.57 times book value per share.

Are insiders buying LENZ stock?

SEC Form 4 filings show no open-market insider buys at LENZ Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.